September 30, 2020

The Niche

Knoepfler lab stem cell blog

Michael Hiltzik

6 min read

The FDA and its CBER branch have been doing a good job overall in the last 3+ years to tackle the unproven stem cell clinic problem, but lately on the stem cells for COVID-19 front there is reason for real concern. I believe the agency is taking on major risk overall by clearing a vast number of cell therapy trials for COVID-19 mostly without much data, but the clearance of a few programs by for-profit stem cell clinics is especially problematic in my view. FDA on …Read More

7 min read

Stem cell clinics and suppliers have been getting into the business of making promotional films to generate more revenue, but now there’s something very different in the cinematic stem cell arena called From Jail Cell to Stem Cell by filmmaker Doug Orchard. It is at its heart an exposé film about some in my view particularly concerning stem cell and exosome clinics and suppliers. The only other thing similar to this was 2019’s great podcast Bad Batch. Reviewing the movie From Jail Cell to Stem Cell Today’s …Read More

4 min read

By Jeanne Loring There has been news over the last few days about stem cell researchers pulling out from a documentary called “The Healthcare Revolution”.  First to report on June 15 was Erin Allday of the San Francisco Chronicle, followed by David Jensen’s California Stem Cell Report blog, Michael Hiltzik of the LA Times, and Beth Mole of ArsTechnica. The documentary is a multipart series that included interviews with people designated as “Episode Experts”.  I discovered last Thursday (June 13) that I was listed …Read More

3 min read

As I broke the news yesterday, the high-profile fat stem cell clinic firm U.S. Stem Cell (USRM) just lost a groundbreaking court case. Here is the FDA’s official reaction today to the court ruling. Also, since the ruling major media have been covering the court ruling. Here are some examples: From the Washington Post from William Wan and Laurie McGinley we have FDA wins groundbreaking case against for-profit stem cell company. Michael Hiltzik of the LA Times has a blunter headline. Backing the FDA, a …Read More